Field report S-89 / R3 · sheet /deals
M&A & DealsFiled from the territory
Isomorphic Labs raises $5bn in oversubscribed UK tech round
Isomorphic Labs raised $5bn in an oversubscribed Series C co-led by Greenoaks and Sequoia, bringing disclosed external funding since 2025 to roughly $7.7bn.
- Grid
- S-89 / R3
- Surveyed
- November 18, 2026
- Reading
- 3 min read
- Correspondent
- Elena Vasquez

Field notes
- $5 billion (£3.8 billion) raised in an oversubscribed Series C announced on Tuesday.
- Greenoaks and Sequoia Capital co-led the round, with eight other named participants.
- Disclosed external funding reached approximately $7.7 billion since 2025, following a $2.1 billion Series B six months earlier.
- Isomorphic sought a valuation of up to $50 billion, versus roughly $17.5 billion previously, but did not disclose its post-round valuation.
- Founded in 2021, Isomorphic remains in late-stage preclinical development and has not tested its own drug candidates in humans.
By Elena Vasquez
Isomorphic Labs raised $5 billion (£3.8 billion) on Tuesday in an oversubscribed Series C round, placing it among the largest financings in British technology history. The London-based AI drug-discovery group, a Google DeepMind spinout led by Nobel Prize winner Sir Demis Hassabis, raised the capital as investors wagered on AI transforming pharmaceutical research.
Who backed the round?
- Co-leads: Greenoaks and Sequoia Capital, two US venture-capital firms.
- Other participants: Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, Capital G, Temasek and the UK government’s Sovereign AI Fund.
Eight other participants join the two co-leads, giving Isomorphic a broad funding base for the development work ahead.
What valuation did Isomorphic seek?
Reports last month said Isomorphic was seeking a valuation of up to $50 billion, compared with roughly $17.5 billion previously. The $5 billion raise followed those reports, but Isomorphic has not disclosed the valuation produced by the Series C.
The upper figure would represent a $32.5 billion increase, or about 186%, from the previous roughly $17.5 billion level. Neither number constituted a disclosed post-round valuation.
How much capital has Isomorphic secured?
The new injection came six months after Isomorphic secured $2.1 billion in Series B funding. Including Tuesday’s round, the company has raised approximately $7.7 billion in disclosed external funding since 2025.
On those reported figures, the Series C represents about 65% of the $7.7 billion total and exceeds the $2.1 billion Series B by $2.9 billion.
What is Isomorphic building?
Founded in 2021, Isomorphic uses AI to design potential medicines by predicting how molecules interact with biological targets. The company aims to reduce the time and cost of drug development through that approach.
IsoDDE, its proprietary drug-design engine, combines AI simulation models to identify and refine potential treatments across different diseases.
Isomorphic is developing its own medicines for cancer and immune disorders. It also has partnerships with Eli Lilly, Novartis and Johnson & Johnson.
The approach links computational prediction to laboratory validation, so its value depends on turning simulations into candidates that pass preclinical testing and then human trials.
What remains before human trials?
Despite the funding scale, Isomorphic has yet to begin testing its own drug candidates in humans. City AM reported that the company remains in late-stage preclinical development, with encouraging early results across internal oncology and immunology programmes and partnered projects.
That distinction matters because a $7.7 billion funding base can finance longer development timelines without changing the evidentiary threshold for a medicine.
The round will direct capital to three areas as Isomorphic prepares for clinical trials:
- Development of its AI models
- Expansion of its drug pipeline
- Construction of global bioengineering infrastructure
The announcement did not name a first-in-human date, leaving trial entry as the next operational milestone.
What did the principals say?
AI minister Kanishka Narayan called the transaction “one of the biggest Series C rounds in UK tech history.” He said Isomorphic’s work could fundamentally change how new medicines are discovered and accelerate the development of life-changing treatments for patients worldwide.
Narayan also said he was proud that the UK government’s Sovereign AI Fund had made a follow-on investment in Isomorphic, backing its continued global growth.
Sir Demis Hassabis said: “Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
The financing has a clear operational purpose: improve AI models, widen the pipeline and build bioengineering capacity so proprietary candidates can enter human trials. Investors are betting on earlier discovery, while the company has yet to provide clinical evidence from human studies.
Until an Isomorphic candidate enters human testing, the $5 billion round will remain a bet on preclinical promise rather than demonstrated clinical efficacy.
via cityam.com (Source)
More from Elena Vasquez
Show full bio
Staff writer covering companies, deals and strategy in corporate strategy and chief-executive leadership at CEO Frontier.
486 articles